Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02586610
Other study ID # HCRN GI15-213
Secondary ID
Status Withdrawn
Phase Phase 2
First received October 22, 2015
Last updated January 18, 2017
Start date October 2016
Est. completion date December 2020

Study information

Verified date January 2017
Source Hoosier Cancer Research Network
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase II, prospective open label multi-center study in which subjects with stage II-III rectal cancer will be accrued in order to determine the pathological complete response rate of neoadjuvant pembrolizumab in combination with chemoradiation treatment (CRT). Subjects must have a diagnosis of rectal cancer, stage II (T3-4, N0) or stage III (any T, N1-2). Subjects must have received no prior treatments (chemotherapy, pelvic radiation or surgery) for their rectal cancer.

Eligible subjects will receive standard chemoradiation with pembrolizumab administered every 3 weeks on days 1, 22, and 43 of the neoadjuvant interval. In all subjects, restaging endorectal or pelvic MRI with chest and abdominal CT will be performed at 6-8 weeks after completion of neoadjuvant treatment to determine resectability and to rule out any evidence of metastases. Subjects who have resectable disease will undergo surgery within 2-4 weeks of imaging; 8-12 weeks after completion of chemoradiation. Subjects who are found to have unresectable or metastatic disease post treatment with the combination of CRT+ pembrolizumab should receive standard of care definitive treatment per the discretion of their treating physician.


Description:

OUTLINE: This is a multi-center study.

NEOADJUVANT TREATMENT:

All subjects will receive concurrent chemoradiation and pembrolizumab neoadjuvant treatment for 6 weeks:

- Pembrolizumab 200 mg Intravenously (IV) Days 1, 22 and 43

- Capecitabine 825 mg/m2 PO (by mouth) in twice daily doses (daily total 1650 mg/m2) on 5 consecutive days / week Monday-Friday given on the radiation days for 28 days

- Radiation 50.4 Gy (Gray) in daily fractions of 1.8 Gy over a 6 week interval,excludes weekends

POST NEOADJUVANT TREATMENT:

- End of treatment (EOT) 6-8 weeks after last dose of neoadjuvant treatment, all subjects will be assessed to determine resectability. Those with resectable disease will undergo surgery within 2-4 weeks of imaging, 8-12 weeks after completion of chemoradiation. Subjects who are found to have unresectable or metastatic disease post treatment with the combination of CRT+ pembrolizumab should receive standard of care definitive treatment per the discretion of their treating physician.

- Surgical Resection ( 2-4 weeks after restaging imaging and 8-12 weeks after completion of chemoradiation)

- Follow Up

- Post Operative Visit (4-6 weeks after surgery)

- Disease Follow Up -Years 1-2 (per site investigator discretion; suggested every 3-6 months)

- Survival Follow Up - Years 3-5

To demonstrate adequate organ function, all screening labs should be performed within 7 days of treatment initiation:

Hematological:

- Absolute neutrophil count (ANC) ≥1,500 /mcL

- Platelets ≥100,000 / mcL

- Hemoglobin ≥9 g/dL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Renal:

- Serum creatinine ≤1.5 X upper limit of normal (ULN) OR

- Measured or calculated creatinine clearance ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN Glomerular filtration rate (GFR) can also be used in place of creatinine or CrCl

Hepatic:

- Serum total bilirubin ≤ 1.5 X ULN

- Aspartate transaminase (AST) / Serum glutamic oxaloacetic transaminase (SGOT) ≤ 2.5 X ULN

- Alanine aminotransferase (ALT) / Serum glutamic-pyruvic transaminase (SGPT) ≤ 2.5 X ULN

- Albumin ≥2.5 mg/dL

Coagulation:

- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy (as long as PT or PTT is within therapeutic range of intended use of anticoagulants)

- Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy (as long as PT or PTT is within therapeutic range of intended use of anticoagulants)


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2020
Est. primary completion date June 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Diagnosis/Condition for Entry into the Trial:

- Histologically confirmed adenocarcinoma of the rectum

- Clinical stage II (T3-4, N-) or stage III (any T, N+) rectal cancer based on pelvic MRI.

- Tumor located within 12 cm of the anal verge (determined by rigid proctoscopy or flexible sigmoidoscopy).

Subject Inclusion Criteria:

- Be willing and able to provide written informed consent for the trial.

- Be 18 years of age or older on day of signing informed consent.

- Have measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).

- Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion.

- Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

- Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study treatment.

Subject Exclusion Criteria:

- Unresectable disease, as evidenced by invading adjacent organs and surgical resection will not achieve negative margins

- Recurrent rectal cancer

- Evidence of metastatic disease (as determined by chest and abdominal CT).

- Prior malignancy within the prior 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.

- Prior radiation for other diagnoses to the expected rectal cancer treatment fields.

- Prior surgery, radiation, chemotherapy, targeted therapy, or investigational therapy for rectal cancer. NOTE: If subject received major surgery for reason other than rectal cancer, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.

- Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the planned start of study treatment.

- Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).

- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).

- Administration of live vaccine within 30 days of planned start of study therapy. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

- Known history of active TB (Bacillus Tuberculosis)

- Hypersensitivity to pembrolizumab or any of its excipients.

- Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

- Known history of, or any evidence of active, non-infectious pneumonitis.

- Active infection requiring systemic therapy.

- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the site investigator.

- Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

- Serious uncontrolled medical disorder that in the opinion of the site investigator would impair the ability of the subject to receive protocol therapy.

- Unable or unwilling to participate a study related procedure, including MRI.

- Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab
Pembrolizumab 200 mg IV Days 1, 22 and 43
Capecitabine
Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
Radiation:
Radiation Therapy
Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Osama Rahma, MD Hoosier Cancer Research Network, Merck Sharp & Dohme Corp.

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological Complete Response (pCR) Rate Proportion of subjects with pathological complete response (pCR) as demonstrated by the absence of residual invasive cancer on evaluation of the complete resected rectal specimen. Time from start of neoadjuvant chemoradiation until surgical resection (estimate up to 12 weeks after completion of chemoradiation)
Secondary Density of CD8(+) Tumor-Infiltrating Lymphocytes (TIL) Estimate the density of CD8 TILs in the tumor at baseline and post-neoadjuvant treatment Time from baseline until completion of post-neoadjuvant treatment (estimate up to 8 weeks after completion of chemoradiation)
Secondary Response Rate (RR) RR of subjects treated with the combination of chemoradiation and pembrolizumab, assessed using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria. Time from registration to documented progression or subject death from any cause, assessed up to 42 months
Secondary Disease Free Survival (DFS) DFS of subjects treated with the combination of chemoradiation and pembrolizumab, assessed using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) criteria. Time from start of protocol treatment to the date of progression or death from any cause, whichever occurs first, assessed up to 42 months
Secondary Overall Survival (OS) OS outcomes assessed using Kaplan-Meier Survival Analysis Subjects who have not died while on study or are lost to follow up will be censored at their last contact date. Time from start of protocol treatment to death from any cause, assessed up to 42 months
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1